The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Prefilled Syringe Fill / Finish Services Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    February 2020

  • Pages
    267

  • View Count
    2845

Example Insights

Prefilled Syringe Fill Finish Services Market 2020 - 2030-Context 	Prefilled Syringe Fill Finish Services Market 2020 - 2030-Service Providers Prefilled Syringe Fill Finish Services Market 2020 - 2030-Different Geographies
Prefilled Syringe Fill Finish Services Market 2020 - 2030-Distribution by Location Prefilled Syringe Fill Finish Services Market 2020 - 2030-Recent Expansions Prefilled Syringe Fill Finish Services Market 2020 - 2030-Capacity Analysis
Prefilled Syringe Fill Finish Services Market 2020 - 2030-Demand vs Supply Analysis Prefilled Syringe Fill Finish Services Market 2020 - 2030-Drug Developers Prefilled Syringe Fill Finish Services Market 2020 - 2030-Caste Study
Prefilled Syringe Fill Finish Services Market 2020 - 2030-Market Forecast Prefilled Syringe Fill Finish Services Market 2020 - 2030-Segmentation  

 

Overview

Among drug delivery devices, prefilled syringes represent one of the fastest growing primary packaging formats, which are also designed for dose administration. In fact, over the past ten years, there has been an evident increase in the development of parenteral drugs (especially with the introduction of several classes of biologics), which has resulted in an increased consumption of prefilled syringes, by approximately three fold.  The sustained preference for such products can be attributed to the fact that prefilled syringes are safe and easy-to-use, and current variants are designed with provisions to reduce dosing errors, the risk of occlusions, extravasation and phlebitis.  Owing to the aforementioned benefits, several injectable drugs (such as Humira®, Enbrel®, Avastin®, PREVNAR 13®, ALPROLIX® and Benefix®), diluents and other products requiring parenteral administration, are packaged in prefilled syringes.  In fact, over the past seven years, around 90 drugs have been approved in combination with prefilled syringes across different geographies, including the North America, Europe and Asia-Pacific.  Moreover, several clinical-stage drugs are being evaluated in combination with prefilled syringes, across different phases of development.  

The filling of sterile drugs into prefilled syringes (and other primary drug containers) is considered to be one of the most crucial steps in the pharmaceutical production process. Proper fill / finish operations, carried out under aseptic conditions, is a necessity for not only maintaining pharmacological efficacy and quality, but also ensuring end user safety. The prefilled syringe filling operation is considered complex as it requires close monitoring of both the syringe fill volume as well as the headspace between the liquid in the syringe and the bottom of the plunger.  Additionally, the rise in complexity of small molecule APIs and the increasing diversity of biologic drugs have also contributed towards the demand for advanced aseptic fill / finish operations.  A number of small-sized companies and some large companies have outsourced their fill / finish operations to contract service providers. According to the 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, biomanufacturers have been shown to outsource over 30% of their fill / finish operations. With the increase in the demand for prefilled syringes, along with the growing complexity of fill / finish processes, the outsourcing of these operations is likely to increase further in the future.  Currently, over 100 companies are actively providing fill / finish services for prefilled syringes. In order to cope up with the current and future market demand, service providers are actively investing in expanding their existing infrastructure and capabilities; companies are also expanding their client reach through service agreements in the past few years. Given that around 55% of drug candidates in the global R&D pipeline are injectables, the opportunities for prefilled syringe developers / manufacturers and affiliated service providers is anticipated to continue to grow over the next decade.  In addition, owing to the recent COVID-19 pandemic, an increase in the development initiatives for the vaccines is likely to be witnessed in the near future. This is expected to significantly raise the demand for prefilled syringes, providing an additional impetus to the overall fill / finish services market.

Scope of the Report

The ‘Prefilled Syringe Fill / Finish Service Providers, 2020-2030’ report features an extensive study of the current market landscape and future opportunities for contract service providers offering fill finish services for prefilled syringes. The study features an in-depth analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes: 

  • A detailed review of the overall landscape of companies offering contract fill / finish services for prefilled syringes, along with analyses based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of the headquarters, location of fill / finish facilities, type of drug molecule (small molecule and biologic), syringe barrel material (glass and plastic), syringe fill volume and additional services offered (drug formulation, regulatory support, labelling and packaging, terminal sterilization, storage and logistics). In addition, the chapter includes details on prefilled syringe fill / finish installed capacity of the service providers.    
  • Tabulated profiles of key players (shortlisted based on a proprietary criterion) across key geographies, such as North America, Europe and Asia-Pacific. Each profile provides an overview of the company, information on its overall service portfolio, fill / finish facilities, financial performance (if available), and details on recent developments as well as an informed future outlook. 
  • An analysis of the recent developments (since 2015) pertaining to contract fill / finish services, based on various parameters, such as year of development, type of activity / development (collaboration and expansions), scale of operation of the project, location of expanded facility, type of drug molecule involved and additional services offered. 
  • An estimate of the global, contract fill / finish capacity of prefilled syringes, by taking into consideration the capacities of various fill / finish service providers (as available on respective company websites), collected via secondary and primary research. The study examines the distribution of number of prefilled syringe units and volume of drug filled, based on the company size of manufacturer (small-sized, mid-sized and large), scale of operation (preclinical / clinical and commercial), location of headquarters and fill / finish facilities (North America, Europe and Asia-Pacific) and type of drug molecule (small molecule and biologics).
  • An informed estimate of the annual demand for fill / finish of prefilled syringes (in number of units), taking into account the marketed drugs available in prefilled syringes and other relevant parameters, such as target patient population, dosing frequency and dose strength. The study provides the distribution of the annual demand, based on the geography (North America (US), Europe (UK, France, Italy, Spain, Germany and rest of Europe), Latin America (Brazil, Mexico, Argentina and rest of Latin America), Asia-Pacific (Japan, China, India, South Korea and rest of Asia-Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and rest of the Middle East)), type of drug molecule (small molecule and biologics), therapeutic area (blood disorders, infectious diseases, metabolic disorders, oncological disorders and others), syringe barrel material (glass and plastic) and number of barrel chambers (single chamber and dual chamber).
  • A detailed demand and supply assessment of geographies, based on a number of parameters, such as the number of prefilled syringe combination product developers, number of prefilled syringe manufacturers, number of prefilled syringe fill / finish service providers, number of prefilled syringe fill / finish facilities, capacity and demand for prefilled syringes in that particular geographical region. 
  • An analysis presenting potential strategic partners (primarily drug developers) for prefilled syringe fill / finish service providers, based on different parameters, such as developer strength, pipeline strength, type of drug molecule, target therapeutic area and location of the headquarters of the company. 
  • A discussion on the potential growth areas, such as growing injectable drugs pipeline, increasing popularity of prefilled syringes, rise in preference for  outsourcing of fill / finish operations, technological advancements in aseptic fill / finish processes, and growing opportunities in the Asia-Pacific region. 
  • A review of the landscape of prefilled syringe manufacturers, featuring a list of key prefilled syringes and their manufacturers, analyzed based on a number of relevant parameters, such as syringe barrel material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) barrel volume, year of establishment and location of the headquarters of manufacturers.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall pharmaceutical and biopharmaceutical market, cost of goods sold, direct manufacturing costs, share of drug product manufacturing costs, and outsourcing trends related to fill / finish operations, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] scale of operation (preclinical, clinical and commercial), [B] key geographical regions (North America (the US), Europe (the UK, France, Italy, Spain, Germany and rest of Europe), Asia-Pacific (Japan, China, India, South Korea and rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina and Rest of Latin America), Middle East and Africa (Saudi Arabia, UAE, Africa and Rest of MEA)), [C] type of drug molecule (small molecule and biologic),  [D] key therapeutic areas (blood disorders, infectious diseases, metabolic disorders, oncological disorders, neurological disorders, autoimmune disorders and others), [E] syringe barrel material (glass and plastic) and [F] number of barrel chambers (single chamber and dual chamber). To account for the uncertainties associated with the fill / finish of prefilled syringes and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Gilles Devillers, President and Cofounder, Bio Elpida
  • Kirti Maheshwari, Chief Technical Officer, Intas Pharmaceuticals
  • Gregor Kawaletz, Chief Commercial Officer, IDT Biologika
  • Michael Dekner, Associate Director, Head of Process Sciences Formulation and Fill / Finish, Takeda
  • Purushottam Singnurkar, Research Director and Head of Formulation Development, Syngene
  • Jesse Fourt, Design Director, IDEO 

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
 

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the prefilled syringe fill / finish contract services market in the mid to long term.

Chapter 3 provides a general introduction to prefilled syringes, focusing on their advantages, classification, overall manufacturing process and a detailed discussion on the fill / finish process. The chapter features a detailed discussion on the need for outsourcing within the prefilled syringes industry and highlights the key operations outsourced by the pharmaceutical players, including fill / finish operations. Additionally, the chapter also highlights the key considerations for selecting a fill / finish service provider, along with the benefits and risks associated with outsourcing fill / finish operations.

Chapter 4 provides an overview of the overall prefilled syringe fill / finish contract service providers. It features in-depth analyses, based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of the headquarters, location of affiliated fill / finish facilities, type of drug molecule (small molecule and biologics), syringe barrel (glass and plastic), syringe fill volume and number of additional services offered (drug formulation, regulatory support, labelling and packaging, terminal sterilization, storage and logistics). In addition, the chapter includes details on prefilled syringe fill / finish installed capacity of the service providers.

Chapter 5 features tabulated profiles of some of the key players that are active in the prefilled syringe fill / finish services market in North America. Each profile presents a brief overview of the company, its overall contract service offerings highlighting the capabilities of drug product facilities (if available), financial information (if available), recent developments and a section on future outlook. 

Chapter 6 features tabulated profiles of some of the key players that are active in the prefilled syringe fill / finish services market in Europe. Each profile presents a brief overview of the company, its overall contract service offerings highlighting the capabilities of drug product facilities (if available), financial information (if available), recent developments and a section on future outlook.  

Chapter 7 features tabulated profiles of some of the key players that are active in the prefilled syringe fill / finish services market in the Asia-Pacific. Each profile presents a brief overview of the company, its overall contract service offerings highlighting the capabilities of drug product facilities (if available), financial information (if available), recent developments and a section on future outlook.

Chapter 8 features an elaborate analysis and discussion on the various recent developments that have taken place in this domain, since 2015. It includes a brief description of the purpose of the recent development (including collaborations and expansions) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of development, type of activity / development (collaboration and expansions), scale of operation of the project, location of expanded facility, type of drug molecule involved and additional services offered.

Chapter 9 features a comprehensive analysis of the installed global prefilled syringe fill / finish capacity, by taking into consideration the container processing capacities of various fill / finish service providers (as available on respective company websites). The study examines the distribution of global, prefilled syringe fill / finish capacity of the industry in terms of number of packaging units and volume of drug filled, based on the company size of manufacturer (small-sized, mid-sized and large), scale of operation (preclinical / clinical and commercial), location of headquarters and fill / finish facilities (North America, Europe and Asia Pacific) and type of drug molecule (small molecule and biologics).

Chapter 10 features a comprehensive analysis of the annual demand for fill / finish of prefilled syringes (in number of units), taking into account the marketed drugs available in combination with prefilled syringes, such as target patient population, dosing frequency and dose strength. The study provides the distribution of the annual demand, based on the geography (North America (the US), Europe (the UK, France, Italy, Spain, Germany and rest of Europe), Latin America (Brazil, Mexico, Argentina and rest of Latin America), Asia Pacific (Japan, China, India, South Korea and rest of Asia-Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and rest of the Middle East)), type of drug molecule (small molecule and biologics), therapeutic area (blood disorders, infectious diseases, metabolic disorders, oncological disorders and others), syringe barrel material (glass and plastic) and number of barrel chambers (single chamber and dual chamber).

Chapter 11 features a detailed demand and supply assessment of geographies, based on a number of parameters, such as the number of prefilled syringe combination product developers, number of prefilled syringe manufacturers, number of prefilled syringe fill / finish service providers, number of prefilled syringe fill / finish facilities, capacity and demand for prefilled syringes in that particular geographical region. 

Chapter 12 features an insightful analysis, highlighting potential strategic partners (primarily drug developers) for prefilled syringe fill / finish service providers, based on different parameters, such as developer strength, pipeline strength, type of drug molecule, target therapeutic area and location of the headquarters of the company.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the likely growth of the prefilled syringe fill / finish services market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] scale of operation (preclinical, clinical and commercial), [B] key geographical regions (North America (the US), Europe (the UK, France, Italy, Spain, Germany and rest of Europe), Asia-Pacific (Japan, China, India, South Korea and rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina and Rest of Latin America), Middle East and Africa (Saudi Arabia, UAE, Africa and Rest of MEA)), [C] type of drug molecule (small molecules and biologics),  [D] key therapeutic areas (blood disorders, infectious diseases, metabolic disorders, oncology disorders, neurological disorders, autoimmune disorders and others), [E] syringe barrel material (glass and plastic) and [F] number of barrel chambers (single chamber and dual chamber).

Chapter 14 features a detailed discussion on the various potential growth areas, such as growing injectable drugs pipeline, increasing popularity of prefilled syringes, rise in preference for  outsourcing of fill / finish operations, technological advancements in aseptic fill / finish processes, and growing opportunities in the Asia-Pacific region. 

Chapter 15 is a case study which provides an overview of the landscape of 20 pharmaceutical companies that claim to manufacture prefilled syringes. It features an in-depth analyses, based on a number of relevant parameters, such as syringe barrel material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) barrel volume, year of establishment, company size and location of the headquarters of manufacturers.

Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the prefilled syringe fill / finish contract manufacturing domain. In this study, we spoke to Gilles Devillers (President and Cofounder, Bio Elpida), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Michael Dekner (Associate Director, Head of Process Sciences Formulation and Fill / Finish, Takeda), Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene) and Jesse Fourt (Design Director, IDEO).

Chapter 18 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Chapter Overview
1.2. Scope of the Report
1.3. Research Methodology
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Prefilled Syringes
3.2.1. Classification of Prefilled Syringes
3.2.2. Manufacturing of Prefilled Syringes
3.2.3. Advantages of Prefilled Syringes
3.2.3.1. Benefits to Healthcare Professionals and End Users
3.2.3.2. Benefits to Manufacturers

3.3. Fill / Finish Processing of Prefilled Syringes
3.3.1. Steps Involved in Fill / Finish Process
3.3.2. Methods of Filling and Stoppering of Prefilled Syringes
3.3.3. Prefilled Syringe Filling Technologies

3.4. Factors Contributing to the Growth of Prefilled Syringe Fill / Finish Market
3.5. Need for Outsourcing Fill / Finish Operations of Sterile Injectables
3.6. Advantages of Outsourcing Fill / Finish Services
3.7. Risks Associated with Outsourcing of Fill / Finish Operations
3.8. Key Considerations While Selecting a Fill / Finish Service Provider

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Prefilled Syringe Fill / Finish Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Location of Prefilled Syringe Fill / Finish Facilities
4.2.6. Analysis by Type of Drug Molecule
4.2.7. Analysis by Syringe Barrel Material
4.2.8. Analysis by Syringe Fill Volume
4.2.9. Analysis by Additional Services Offered
4.2.10. Heat Map: Analysis by Company Size and Location of Headquarters
4.2.11. Logo Landscape: Analysis by Company Size and Type of Drug Molecule
4.2.12. Geographical Map: Analysis by Scale of Operation and Location of Fill / Finish Facilities
4.2.13. Grid Representation: Distribution by Year of Establishment, Company Size and Type of Drug Molecule

5. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
5.1. Chapter Overview
5.2. Ajinomoto Bio-Pharma Services
5.2.1. Company Overview
5.2.2. Recent Developments and Future Outlook

5.3. AMRI
5.3.1. Company Overview
5.3.2. Recent Developments and Future Outlook

5.4. BioPharma Solutions
5.4.1. Company Overview
5.4.2. Recent Developments and Future Outlook

5.5. Emergent BioSolutions
5.5.1. Company Overview
5.5.2. Recent Developments and Future Outlook

5.6. Patheon (a Thermo Fisher Scientific Company)
5.6.1. Company Overview
5.6.2. Recent Developments and Future Outlook

6. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN EUROPE: COMPANY PROFILES
6.1. Chapter Overview
6.2. Consort Medical
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook

6.3. EVER Pharma
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. GlaxoSmithKline
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. IDT Biologika
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook

6.6. Rentschler Biopharma
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook

6.7. Siegfried
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook

6.8. Vetter Pharma
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook

7. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Biocon
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook

7.3. Intas Pharmaceuticals
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook

7.4. Kemwell Biopharma
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook

7.5. Square Pharmaceuticals
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook

8. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS: RECENT DEVELOPMENTS
8.1. Chapter Overview
8.2. List of Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Expanded Scale of Operation
8.2.4. Analysis by Location of Expansion Project
8.2.5. Analysis by Type of Drug Molecule Involved
8.2.6. Analysis by Additional Services Offered (Expansion Specific)

8.3. Partnership Models
8.4. List of Partnerships and Collaborations
8.4.1. Analysis by Year of Partnership
8.4.2. Analysis by Type of Partnership
8.4.3. Analysis by Scale of Operation (Deal Specific)
8.4.4. Analysis by Additional Services Offered (Deal Specific)

9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Methodology

9.3. Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units)
9.3.1. Analysis by Company Size
9.3.2. Analysis by Scale of Operation
9.3.3. Analysis by Location of Headquarters
9.3.4. Analysis by Location of Fill / Finish Facilities
9.3.5. Analysis by Type of Drug Molecule

9.4. Global, Prefilled Syringe Fill / Finish Capacity (by Volume)
9.4.1. Analysis by Company Size (Manufacturer)
9.4.2. Analysis by Scale of Operation
9.4.3. Analysis by Location of Headquarters
9.4.4. Analysis by Location of Fill / Finish Facilities
9.4.5. Analysis by Type of Drug Molecule

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodology

10.3. Global Demand for Prefilled Syringes Fill / Finish Services
10.3.1. Global Demand for Commercialized Prefilled Syringes Fill / Finish Services
10.3.1.1. Analysis by Geography
10.3.1.1.1. North America
10.3.1.1.2. Europe
10.3.1.1.3. Asia-Pacific
10.3.1.1.4. Latin America
10.3.1.1.5. Middle East and Africa

10.3.1.2. Analysis by Syringe Barrel Material
10.3.1.3. Analysis by Number of Barrel Chambers
10.3.1.4. Analysis by Type of Drug Molecule
10.3.1.5. Analysis by Therapeutic Area
10.3.1.6. Analysis by Specialty Syringes

10.3.2. Global Demand for Clinical Prefilled Syringes Fill / Finish Services
10.4. Demand and Supply Analysis
10.4.1. Demand and Supply Analysis (Scenario 1)
10.4.2. Demand and Supply Analysis (Scenario 2)
10.4.3. Demand and Supply Analysis (Scenario 3)

11. GEOGRAPHICAL ASSESSMENT OF DEMAND AND SUPPLY
11.1. Chapter Overview
11.2. Assumptions and Key Parameters

11.3. Demand and Supply Assessment in North America
11.3.1. Key Geographies
11.3.1.1. US

11.4. Demand and Supply Assessment in Europe
11.4.1. Key Geographies
11.4.1.1. France
11.4.1.2. Germany
11.4.1.3. Italy

11.5. Demand and Supply Assessment in Asia-Pacific Region
11.5.1. Key Geographies
11.5.1.1. India
11.5.1.2. Japan

12. LIKELY PARTNER ANALYSIS
12.1. Chapter Overview
12.2. Methodology and Key Parameters

12.3. Likely Partner Analysis
12.3.1. Opportunities in North America
12.3.1.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
12.3.1.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers
12.3.2. Opportunities in Europe
12.3.2.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
12.3.2.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers

12.3.3. Opportunities in Asia-Pacific and Rest of the World
12.3.3.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
12.3.3.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions

13.3. Overall Prefilled Syringe Fill / Finish Services Market, 2020-2030
13.3.1. Prefilled Syringe Fill / Finish Services Market: Distribution by Scale of Operation, 2020-2030

13.3.2. Prefilled Syringe Fill / Finish Services Market: Distribution by Geographical Region
13.3.2.1. Prefilled Syringe Fill / Finish Services Market in North America
13.3.2.2. Prefilled Syringe Fill / Finish Services Market in Europe
13.3.2.3. Prefilled Syringe Fill / Finish Services Market in Asia-Pacific
13.3.2.4. Prefilled Syringe Fill / Finish Services Market Latin America
13.3.2.5. Prefilled Syringe Fill / Finish Services Market in Middle East and Africa

13.3.3. Prefilled Syringe Fill / Finish Services Market: Distribution by Type of Drug Molecule, 2020-2030
13.3.4. Prefilled Syringe Fill / Finish Services Market: Distribution by Therapeutic Area
13.3.5. Prefilled Syringe Fill / Finish Services Market: Distribution by Syringe Barrel Material, 2020-2030
13.3.6. Prefilled Syringe Fill / Finish Services Market: Distribution by Number of Barrel Chambers, 2020-2030

14. FUTURE GROWTH OPPORTUNITIES
14.1. Chapter Overview
14.2. Growing Injectable Drugs Pipeline
14.3. Increase in Popularity of Prefilled Syringes
14.4. Rise in Preference for Outsourcing Fill / Finish Activities
14.5. Advances in Aseptic Fill / Finish Technologies
14.6. Growing Opportunities in the Asia-Pacific Region

15. CASE STUDY: PREFILLED SYRINGE MANUFACTURERS
15.1. Chapter Overview
15.2. Prefilled Syringes: List of Available / Under Development Devices
15.2.1. Analysis by Syringe Barrel Material
15.2.2. Analysis by Number of Barrel Chambers
15.2.3. Analysis by Type of Needle System
15.2.4. Analysis by Barrel Volume

15.3. Prefilled Syringes: List of Manufacturers
15.3.1. Analysis by Year of Establishment
15.3.2. Analysis by Location of Headquarters

16. CONCLUDING REMARKS
16.1. Chapter Overview
16.2. Key Takeaways

17. INTERVIEW TRANSCRIPTS
17.1. Chapter Overview
17.2. Bio Elpida
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Gilles Devillers, President and Cofounder

17.3. Intas Pharmaceuticals
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Kirti Maheshwari, Chief Technical Officer

17.4. IDT Biologika
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer

17.5. Takeda
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Michael Dekner, Associate Director, Head of Process Sciences Formulation and Fill / Finish

17.6. Synegene
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Purushottam Singnurkar, Research Director and Head of Formulation Development

17.7. IDEO
17.7.1. Company Snapshot
17.7.2. Interview Transcript: Jesse Fourt, Design Director

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES

List Of Figures

Figure 3.1 Prefilled Syringe Manufacturing: Common Processes
Figure 3.2 Prefilled Syringes: Fill / Finish Process
Figure 3.3 Risks and Challenges of Outsourcing Fill / Finish Operations
Figure 3.4 Key Considerations while Selecting a Fill / Finish Service Provider
Figure 4.1 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 4.2 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size
Figure 4.3 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 4.4 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 4.5 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Prefilled Syringe Fill / Finish Facilities
Figure 4.6 Prefilled Syringe Fill / Finish Service Providers: Distribution by Type of Drug Molecule
Figure 4.7 Prefilled Syringe Fill / Finish Service Providers: Distribution by Syringe Barrel Material
Figure 4.8 Prefilled Syringe Fill / Finish Service Providers: Distribution by Syringe Fill Volume
Figure 4.9 Prefilled Syringe Fill / Finish Service Providers: Distribution by Additional Services Offered
Figure 4.10 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size and Type of Drug Molecule
Figure 4.11 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation and Location of Fill / Finish Facilities
Figure 4.12 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment, Company Size and Type of Drug Molecule
Figure 8.1 Expansions: Distribution by Year of Expansion, 2015-2019
Figure 8.2 Expansions: Distribution by Type of Expansion
Figure 8.3 Expansions: Distribution by Expanded Scale of Operation
Figure 8.4 Expansions: Distribution by Location of Expansion Project
Figure 8.5 Expansions: Distribution by Type of Drug Molecule Involved
Figure 8.6 Expansions: Distribution by Additional Services Offered (Expansion Specific)
Figure 8.7 Partnerships and Collaborations: Cumulative Trend by Year, 2015- January 2020
Figure 8.8 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.9 Partnerships and Collaborations: Distribution by Scale of Operation (Deal Specific)
Figure 8.10 Partnerships and Collaborations: Distribution by Additional Services Offered (Deal Specific)
Figure 9.1 Global, Prefilled Syringe Fill / Finish Capacity: Distribution of Capacity by Company Size (Sample Data Set)
Figure 9.2 Global, Prefilled Syringe Fill / Finish Capacity: Distribution by Company Size (in Million Units)
Figure 9.3 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Scale of Operation (in Million Units)
Figure 9.4 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Location of Headquarters (in Million Units)
Figure 9.5 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Location of Fill / Finish Facilities (in Million Units)
Figure 9.6 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Type of Drug Molecule (in Million Units)
Figure 9.7 Global, Prefilled Syringe Fill / Finish Capacity: Distribution by Company Size (in Million Liters)
Figure 9.8 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Scale of Operation (in Million Liters)
Figure 9.9 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Location of Headquarters (in Million Liters)
Figure 9.10 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Location of Fill / Finish Facilities (in Million Liters)
Figure 9.11 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Type of Drug Molecule (in Million Liters)
Figure 10.1 Global, Demand for Prefilled Syringe Fill / Finish Services
Figure 10.2 Global, Demand for Commercialized Prefilled Syringe Fill / Finish Services
Figure 10.3 Global, Demand for Prefilled Syringe Fill / Finish Services: Share of North America
Figure 10.4 Global, Demand for Prefilled Syringe Fill / Finish Services: Share of Europe
Figure 10.5 Global, Demand for Prefilled Syringe Fill / Finish Services: Share of Asia-Pacific
Figure 10.6 Global, Demand for Prefilled Syringe Fill / Finish Services: Share of Latin America
Figure 10.7 Global, Demand for Prefilled Syringe Fill / Finish Services: Share of Middle East and Africa
Figure 10.8 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Syringe Barrel Material
Figure 10.9 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Number of Barrel Chambers
Figure 10.10 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Type of Drug Molecule
Figure 10.11 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Therapeutic Area
Figure 10.12 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Specialty Syringes
Figure 10.13 Global, Demand for Clinical Prefilled Syringe Fill / Finish Services
Figure 10.14 Global, Prefilled Syringe Fill / Finish Services: Demand and Supply Dynamics (Scenario 1)
Figure 10.15 Global, Prefilled Syringe Fill / Finish Services: Demand and Supply Dynamics (Scenario 2)
Figure 10.16 Global, Prefilled Syringe Fill / Finish Services: Demand and Supply Dynamics (Scenario 3)
Figure 11.1 Demand and Supply Assessment: North America
Figure 11.2 Demand and Supply Assessment: US
Figure 11.3 Demand and Supply Assessment: Europe
Figure 11.4 Demand and Supply Assessment: France
Figure 11.5 Demand and Supply Assessment: Germany
Figure 11.6 Demand and Supply Assessment: Italy
Figure 11.7 Demand and Supply Assessment: Asia-Pacific Region
Figure 11.8 Demand and Supply Assessment: India
Figure 11.9 Demand and Supply Assessment: Japan
Figure 12.1 Likely Partner Analysis: Distribution by Company Size and Location of Headquarters
Figure 13.1 Overall Prefilled Syringe Fill / Finish Services Market, 2020-2030 (USD Billion)
Figure 13.2 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Scale of Operation (USD Million)
Figure 13.3 Prefilled Syringe Fill / Finish Services Market: Distribution by Geographical Location (USD Million)
Figure 13.4 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Geographical Location, North America (USD Million)
Figure 13.5 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Geographical Location, Europe (USD Million)
Figure 13.6 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Geographical Location, Asia-Pacific (USD Million)
Figure 13.7 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Geographical Location, Latin America (USD Million)
Figure 13.8 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Geographical Location, Middle East and Africa (USD Million)
Figure 13.9 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Type of Drug Molecule (USD Million)
Figure 13.10 Prefilled Syringe Fill / Finish Services Market: Distribution by Therapeutic Area (USD Million)
Figure 13.11 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Syringe Barrel Material (USD Million)
Figure 13.12 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Number of Barrel Chambers (USD Million)
Figure 14.1 Growth Opportunities for Prefilled Syringe Fill / Finish Service Providers
Figure 14.2 Pipeline Distribution by Route of Administration
Figure 14.3 FDA Approved Biologics and Biosimilars, 2014-2019
Figure 14.4 Approved Prefilled Syringe Combination Products: Cumulative Distribution by Approval Year
Figure 14.5 Clinical Stage Prefilled Syringes Combination Products: Distribution by Phase of Development
Figure 15.1 Prefilled Syringes: Distribution by Syringe Barrel Material
Figure 15.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 15.3 Prefilled Syringes: Distribution by Type of Needle System
Figure 15.4 Prefilled Syringes: Distribution by Barrel Volume
Figure 15.5 Prefilled Syringe Developers: Distribution by Year of Establishment
Figure 15.6 Prefilled Syringe Developers: Distribution by Location of Headquarters

List Of Table

Table 3.1 Classification of Prefilled Syringes
Table 4.1 Prefilled Syringe Fill / Finish Service Providers: List of Companies
Table 4.2 Prefilled Syringe Fill / Finish Service Providers: Information on Location of Fill / Finish Facilities
Table 4.3 Prefilled Syringe Fill / Finish Service Providers: Information on Type of Drug Molecule
Table 4.4 Prefilled Syringe Fill / Finish Service Providers: Information on Syringe Barrel Material
Table 4.5 Prefilled Syringe Fill / Finish Service Providers: Information on Syringe Fill Volume Range
Table 4.6 Prefilled Syringe Fill / Finish Service Providers: Information on Additional Services Offered
Table 4.7 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size and Location of Headquarters
Table 4.8 Prefilled Syringe Fill / Finish Service Providers: Information on Fill / Finish Capability
Table 5.1 Prefilled Syringes Fill / Finish Service Providers in North America: List of Profiled Companies
Table 5.2 Ajinomoto Bio-Pharma Services: Company Snapshot
Table 5.3 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 5.4 AMRI: Company Snapshot
Table 5.5 AMRI: Recent Developments and Future Outlook
Table 5.6 BioPharma Solutions: Company Snapshot
Table 5.7 BioPharma Solutions: Recent Developments and Future Outlook
Table 5.8 Emergent BioSolutions: Company Snapshot
Table 5.9 Emergent BioSolutions: Recent Developments and Future Outlook
Table 5.10 Patheon: Company Snapshot
Table 5.11 Patheon: Recent Developments and Future Outlook
Table 6.1 Prefilled Syringe Fill / Finish Service Providers in Europe: List of Profiled Companies
Table 6.2 Consort Medical: Company Snapshot
Table 6.3 Consort Medical: Recent Developments and Future Outlook
Table 6.4 EVER Pharma: Company Snapshot
Table 6.5 EVER Pharma: Recent Developments and Future Outlook
Table 6.6 GlaxoSmithKline: Company Snapshot
Table 6.7 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.8 IDT Biologika: Company Snapshot
Table 6.9 IDT Biologika: Recent Developments and Future Outlook
Table 6.10 Rentschler Biopharma: Company Snapshot
Table 6.11 Rentschler Biopharma: Recent Developments and Future Outlook
Table 6.12 Siegfried: Company Snapshot
Table 6.13 Siegfried: Recent Developments and Future Outlook
Table 6.14 Vetter Pharma: Company Snapshot
Table 6.15 Vetter Pharma: Recent Developments and Future Outlook
Table 7.1 Prefilled Syringes Fill / Finish Service Providers in Asia-Pacific: List of Profiled Companies
Table 7.2 Biocon: Company Snapshot
Table 7.3 Biocon: Recent Developments and Future Outlook
Table 7.4 Intas Pharmaceuticals: Company Snapshot
Table 7.5 Intas Pharmaceuticals: Recent Developments and Future Outlook
Table 7.6 Kemwell Biopharma: Company Snapshot
Table 7.7 Kemwell Biopharma: Recent Developments and Future Outlook
Table 7.8 Square Pharmaceuticals: Company Snapshot
Table 7.9 Square Pharmaceuticals: Recent Developments and Future Outlook
Table 8.1 Prefilled Syringe Fill / Finish Service Providers: Recent Expansions, 2015-2019
Table 8.2 Expansions: Information on Additional Services Offered
Table 8.3 Prefilled Syringe Fill / Finish Service Providers: Partnerships and Collaborations, 2015-2020
Table 8.4 Partnerships: Information on Type of Services
Table 9.1 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Average Capacity by Company Size (Sample Data Set)
Table 10.1 Global Prefilled Syringe Fill / Finish Services Annual Supply, 2020-2030 (Million Units)
Table 10.2 Global Annual Outsourcing Demand for Prefilled Syringe Fill / Finish Services (Million Units)
Table 10.3 Global Annual Outsourcing Demand for Prefilled Syringe Fill / Finish Services (Million Units)
Table 10.4 Global Annual Outsourcing Demand for Prefilled Syringe Fill / Finish Services (Million Units)
Table 11.1 Demand and Supply Assessment: North America
Table 11.2 Demand and Supply Assessment: Europe
Table 11.3 Demand and Supply Assessment: Asia-Pacific
Table 12.1 Opportunities in North America: Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
Table 12.2 Opportunities in North America: Likely Partners for Prefilled Syringe Fill / Finish Service Providers
Table 12.3 Opportunities in Europe: Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
Table 12.4 Opportunities in Europe: Likely Partners for Prefilled Syringe Fill / Finish Service Providers
Table 12.5 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
Table 12.6 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Prefilled Syringe Fill / Finish Service Providers
Table 14.1 List of Pharmaceutical Robotics Manufacturers
Table 14.2 List of Companies Supplying Ready-to-Use Packaging Components
Table 14.3 Patent Expiry of Biologics, 2018-2023
Table 15.1 Prefilled Syringes: List of Available / Under Development Devices
Table 15.2 Prefilled Syringes: List of Manufacturers
Table 16.1 Prefilled Syringe Fill / Finish Services Market: Key Takeaways
Table 17.1 Bio Elpida: Key Highlights
Table 17.2 Intas Pharmaceuticals: Key Highlights
Table 17.3 IDT Biologika: Key Highlights
Table 17.4 Takeda: Key Highlights
Table 17.5 Syngene: Key Highlights
Table 17.6 IDEO: Key Highlights
Table 18.1 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
Table 18.2 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size
Table 18.3 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation
Table 18.4 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 18.5 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 18.6 Prefilled Syringe Fill / Finish Service Providers: Distribution by Company Size and Type of Drug Molecule
Table 18.7 Prefilled Syringe Fill / Finish Service Providers: Distribution by Syringe Barrel Material
Table 18.8 Prefilled Syringe Fill / Finish Service Providers: Distribution by Syringe Fill Volume
Table 18.9 Prefilled Syringe Fill / Finish Service Providers: Distribution by Additional Services Offered
Table 18.10 Partnerships and Collaborations: Distribution by Year of Partnership, 2015-2019
Table 18.11 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.12 Partnerships and Collaborations: Distribution by Scale of Operation (Deal Specific)
Table 18.13 Partnerships and Collaborations: Distribution by Additional Services Offered (Deal Specific)
Table 18.14 Most Active Players: Distribution by Number of Partnerships
Table 18.15 Expansions: Distribution by Year of Expansion, 2015-2019
Table 18.16 Expansions: Distribution by Type of Expansion
Table 18.17 Expansions: Distribution by Expanded Scale of Operation
Table 18.18 Expansions: Distribution by Location of Expansion Project
Table 18.19 Expansions: Distribution by Type of Drug Molecule Involved
Table 18.20 Expansions: Distribution by Additional Services Offered (Expansion Specific)
Table 18.21 Global, Prefilled Syringe Fill / Finish Capacity: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Table 18.22 Global, Prefilled Syringe Fill / Finish Capacity: Distribution by Company Size of Manufacturer (in Million Units)
Table 18.23 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Scale of Operation (in Million Units)
Table 18.24 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Location of Headquarters (in Million Units)
Table 18.25 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Location of Fill / Finish Facilities (in Million Units)
Table 18.26 Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units): Distribution by Type of Drug Molecule (in Million Units)
Table 18.27 Global, Prefilled Syringe Fill / Finish Capacity: Distribution by Company Size of Manufacturer (in Million Liters)
Table 18.28 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Scale of Operation (in Million Liters)
Table 18.29 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Location of Headquarters (in Million Liters)
Table 18.30 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Location of Fill / Finish Facilities (in Million Liters)
Table 18.31 Global, Prefilled Syringe Fill / Finish Capacity (by Volume): Distribution by Type of Drug Molecule (in Million Liters)
Table 18.32 Global, Demand for Prefilled Syringe Fill / Finish Services
Table 18.33 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Geography
Table 18.34 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Type of Drug Molecule
Table 18.35 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Therapeutic Area
Table 18.36 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Syringe Barrel Material
Table 18.37 Global, Demand for Prefilled Syringe Fill / Finish Services: Distribution by Number of Barrel Chambers
Table 18.38 Demand and Supply Assessment: North America
Table 18.39 Demand and Supply Assessment: Europe
Table 18.40 Demand and Supply Assessment: Asia-Pacific and Rest of the World
Table 18.41 Likely Partner Analysis: Distribution by Geography
Table 18.42 Overall Prefilled Syringe Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 18.43 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 18.44 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Geographical Location, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 18.45 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Type of Drug Molecule, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 18.46 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 18.47 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Syringe Barrel Material, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 18.48 Prefilled Syringe Fill / Finish Services Market, 2020-2030: Distribution by Number of Barrel Chambers, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 18.49 Prefilled Syringes: Distribution by Syringe Barrel Material
Table 18.50 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 18.51 Prefilled Syringes: Distribution by Type of Needle System
Table 18.52 Prefilled Syringes: Distribution by Barrel Volume
Table 18.53 Prefilled Syringe Manufacturers: Distribution by Year of Establishment
Table 18.54 Prefilled Syringe Manufacturers: Distribution by Company Size
Table 18.55 Prefilled Syringe Manufacturers: Distribution by Location of Headquarters

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. ABB
  2. Abbott
  3. AbbVie
  4. AbbVie Contract Manufacturing
  5. Ablynx
  6. Accord Healthcare
  7. Adamis Pharmaceuticals
  8. Adimmune
  9. Aguettant
  10. AJ Biologics
  11. Ajinomoto Bio-Pharma Services
  12. Akron Biotech
  13. Akums Drugs & Pharmaceuticals
  14. Alanza
  15. Alcami
  16. Alder BioPharmaceuticals
  17. Alfasigma
  18. Alkermes
  19. Alvogen
  20. Alvotech
  21. Amega Biotech
  22. Amgen
  23. Amneal Deutschland GmbH
  24. AMRI
  25. APL
  26. Apobiologix
  27. Aptar Pharma
  28. Aristopharma
  29. Asarina Pharma
  30. AstraZeneca
  31. Austrianova
  32. Automated Systems of Tacoma
  33. Axcellerate Pharma
  34. Bahrain Pharma
  35. Baxter
  36. Becton Dickinson
  37. Berkshire Sterile Manufacturing
  38. Bespak
  39. Beximco Pharma
  40. Bill & Melinda Gates Medical Research Institute
  41. Bio Elpida
  42. Biocad
  43. Biocon
  44. BioConnection
  45. Biogen
  46. Bioinova
  47. Biomedical Advanced Research and Development Authority
  48. BioPharma Solutions
  49. Biotech Vision Care
  50. BirgiMefar
  51. Boehringer Ingelheim
  52. Boehringer Ingelheim BioXcellence
  53. Bone Therapeutics
  54. Braeburn Pharmaceuticals
  55. Bristol-Myers Squibb
  56. Bryllan
  57. CARBOGEN AMCIS
  58. Catalent Biologics
  59. Celltrion
  60. Cenexi
  61. Centrexion Therapeutics
  62. Cerium Pharmaceuticals
  63. Chugai Pharmaceuticals
  64. CinnaGen
  65. Ciron Drugs and Pharmaceutical
  66. Clover Biopharmaceuticals
  67. Coalition for Epidemic Preparedness Innovations
  68. Cobra Biologics
  69. Coherus Biosciences
  70. Combino Pharm
  71. Consort Medical
  72. Cook Pharmica
  73. Corden Pharma
  74. Dalton Pharma Services
  75. Delpharm 
  76. DENSO 
  77. Dhruv Life sciences
  78. DM Bio
  79. Dynavax Technologies
  80. EirGen Pharma
  81. Eli Lilly
  82. Emcure Pharmaceuticals
  83. EMD Serono
  84. Emergent BioSolutions
  85. Eurofins BioPharma
  86. European Medical Contract Manufacturing
  87. Ever Pharma
  88. Evotec
  89. ExCellThera
  90. FACET
  91. FANUC America
  92. Foresee Pharmaceutical
  93. Fresenius Kabi
  94. Fresenius Kabi Contract Manufacturing
  95. Fujifilm
  96. Gadea Pharmaceutical Group
  97. GC Pharma
  98. GeneDesign
  99. Genentech
  100. Generon (Shanghai)
  101. Genmab
  102. Genovior Biotech 
  103. Gerresheimer
  104. Gland Pharma
  105. GlaxoSmithKline
  106. GP Pharm
  107. Grand River Aseptic Manufacturing
  108. Gulf Biotech
  109. Hanmi Pharmaceutical
  110. Health Biotech
  111. Healthcare Pharmaceuticals
  112. Heron Therapeutics
  113. Hetero Drugs
  114. Hetero Healthcare
  115. Hisun Pharmaceuticals USA
  116. IDEO
  117. IDT Biologika
  118. Il-Yang Pharm
  119. Injectalia
  120. Intas Pharmaceuticals
  121. Integrity Bio
  122. Ipsen 
  123. IRISYS
  124. Italfarmaco
  125. Janssen
  126. Johnson & Johnson
  127. Kawasaki Heavy Industries
  128. Kemwell Biopharma
  129. Keryx Biopharmaceuticals
  130. Kilitch Healthcare
  131. Kiniksa Pharmaceuticals
  132. KP Pharmaceutical Technology
  133. KUKA
  134. Kyowa Hakko Kirin
  135. Laboratorios SALVAT 
  136. Leo Pharma
  137. Lifecore Biomedical
  138. LSNE Contract Manufacturing
  139. Lubrizol Life Science Health
  140. Lundbeck
  141. Lyell Immunopharma
  142. Marchesini Group
  143. Massman Automation Designs
  144. Medefil
  145. Medicago
  146. Merck
  147. Metrion Biosciences
  148. Mithra
  149. Mithra Pharmaceuticals
  150. Mitsubishi Electric
  151. Mitsubishi Gas Chemical
  152. Mitsubishi Tanabe Pharma
  153. Momenta Pharmaceuticals
  154. MorphoSys
  155. Mycenax Biotech 
  156. National Institute of Allergy and Infectious Disease
  157. Nemus Bioscience
  158. Nipro
  159. Northway Biotechpharma
  160. Nova Laboratories
  161. Novartis
  162. Ology Bioservices
  163. OmniChem
  164. Ompi
  165. OMRON Industrial Automation
  166. Oncobiologics
  167. Oncotec Pharma Produktion
  168. "Opiant
  169. Pharmaceuticals"
  170. Otsuka Pharmaceutical
  171. Patheon
  172. PCI Pharma Services
  173. Pfizer
  174. Pfizer CentreOne
  175. Pfizer Injectables
  176. Pharmaceutics International
  177. Pierre Fabre
  178. Piramal Enterprises
  179. Pisa Farmacéutica
  180. Polpharma Biologics
  181. Praxis Pharmaceutical
  182. Precision Ocular Metrology
  183. PrimaPharma
  184. PYRAMID Laboratories
  185. Recipharm
  186. Regeneron
  187. Reliance Life Sciences
  188. Rentschler Biopharma
  189. RHEACELL
  190. Roche
  191. Rompharm
  192. Rovi CM
  193. Sabin Vaccine Institute
  194. SAFC
  195. Samsung Bioepis
  196. Samsung Biologics
  197. Sandoz
  198. Sanofi
  199. Saudi Biotech Manufacturing
  200. Schott
  201. Schott-Kaisha
  202. ScinoPharm
  203. Seiko Epson
  204. Selecta Biosciences
  205. Seqirus
  206. Sewa Medicals
  207. Shandong Pharmaceutical Glass
  208. Shandong Weigao
  209. Sharp
  210. Shire
  211. SHL Group
  212. Siegfried
  213. Singota Solutions
  214. SOBI
  215. Sovereign Pharma
  216. Spectrum Pharmaceuticals
  217. Square Pharmaceuticals
  218. Staubli
  219. Stempeutics
  220. Sun Pharma
  221. Sunshine Health Products
  222. Swissfillon
  223. Symphogen
  224. Syngene
  225. Taisei Kako
  226. Taiyo Yakuhin
  227. Takeda
  228. Tanvex BioPharma
  229. Tekpak
  230. Terumo
  231. Teva Pharmaceutical
  232. The United States Department of Health and Human Services (HHS)
  233. Tolmar
  234. Transcoject
  235. TriPharm Services
  236. UCB Biopharma
  237. Unicep
  238. United States Army Medical Materiel Development Activity
  239. Universal Robots
  240. University of California
  241. US Department of Health and Human Services
  242. USV
  243. Valeant Pharmaceuticals
  244. Vanrx Pharmasystems
  245. Vaxart
  246. VELIT Biopharmaceuticals
  247. Vetter Pharma
  248. Vitaeris
  249. VxP Biologics
  250. West Pharmaceuticals
  251. Wockhardt
  252. Yaskawa Electric
  253. YL Biologics 
  254. Zen Pharma
  255. Zhejiang Huahai Pharmaceutical

  256.  

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com